Enzymotec Granted Mexican Patent for INFAT® Uses Related to Promoting Intestinal Health
December 21 2015 - 8:30AM
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and
marketer of innovative bio-active lipid based nutritional
ingredients and medical foods, announced today that INFAT®, the
innovative ingredient that is marketed by Advanced Lipids, an AAK
and Enzymotec joint venture, was granted a patent by the Mexican
Patent Office for uses related to promoting intestinal health.
INFAT®, developed specifically for infant
formula, is a clinically-proven fat ingredient that closely
resembles the composition, structure and nutritional value of the
natural fat found in human breast milk, which is necessary for
proper infant health, development and comfort. The patent relates
to a vegetable-derived, enzymatically prepared lipid composition,
comprising of triglycerides with 15-55% palmitic acid of which at
least 30% are in the middle position, for promoting the development
of beneficial gut flora.
“We are pleased to add another patent to our robust worldwide
intellectual property portfolio, which serves as the cornerstone of
our strategy to lead the market through innovation. We provide our
INFAT® customers with a clear competitive edge,
which puts them at the forefront of a crowded space," commented Mr.
Avner Avissara, CEO of Advanced Lipids and Enzymotec’s VP of Sales
for Infant Nutrition, Nutrition Division. "We remain focused on our
research and development and continue to innovate to further
develop the benefits of INFAT® and create value for our
customers."
Previously published clinical data demonstrated that infants fed
with formula containing INFAT® developed a similar variety of
beneficial gut bacteria as breastfed babies. Beneficial gut
bacteria promote good health and development, and the ability to
prevent infections.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based
products and solutions. The Company develops, manufactures, and
markets innovative bio-active lipid based nutritional ingredients
and medical foods, driven by a deep core of cutting-edge,
proprietary technologies intended to improve people’s health.
For more information, visit www.enzymotec.com.
About Advanced Lipids
Advanced Lipids is a joint venture of AAK and Enzymotec. For
more information, visit www.advancedlipids.com.
Forward Looking Statements
This release may contain forward-looking statements, which
express the current beliefs and expectations of Company management.
Such statements involve a number of known and unknown risks and
uncertainties that could cause our future results, performance or
achievements to differ significantly from the results, performance
or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to
such differences include the following risks: A high proportion of
the sales of the InFat product is sold to end users in China and to
a single company; Growth in the Chinese economy has moderated and
this slowdown and related volatility could adversely impact demand
in China for our products; The demand for products based on Omega-3
and in particular, premium products, such as krill oil, has
declined and may continue to decline following a significant
increase in manufacturing capacity by manufacturers of these
products, resulting in intense competition and price pressure; Our
offering of products as "medical foods" in the United States may be
challenged by regulatory authorities; We rely on our Swedish joint
venture partner to manufacture InFat and certain matters related to
the joint venture are the subject of disagreement in an arbitration
proceeding; We are subject to a degree of customer concentration
and our customers do not enter into long-term purchase commitments
with us; We depend on third parties to obtain raw materials, in
particular krill, necessary for the production of our products; We
are dependent on a single facility that houses the majority of our
operations; We may have to pay royalties with respect to sales of
our krill oil products in the United States or Australia and any
infringement of intellectual property of others could also require
us to pay royalties; Potential future acquisitions of companies or
technologies may distract our management, may disrupt our business
and may not yield the returns expected; We anticipate that the
markets in which we participate will become more competitive and we
may be unable to compete effectively; We may not be able to
successfully expand our production or processing capabilities; Our
ability to obtain krill may be affected by conservation regulation
or initiatives; Our product development cycle is lengthy and
uncertain, and our development or commercialization efforts for our
products may be unsuccessful; and other factors discussed under the
heading "Risk Factors" in the Company's Form 20-F filed with the
Securities and Exchange Commission on March 2, 2015.
Forward-looking statements in this release are made pursuant to the
safe harbor provisions contained in the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
made only as of the date hereof, and the Company undertakes no
obligation to update or revise the forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact:
The Ruth Group
Tram Bui / Lee Roth
Phone: 646-536-7035 / 7012
tbui@theruthgroup.com
lroth@theruthgroup.com
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024